Trospium chloride in elderly patients with idiopathic overactive bladder refractory to mirabegron
https://doi.org/10.37586/2686-8636-4-2025-580-584
Abstract
Overactive bladder (OAB) is urinary urgency, with or without urinary incontinence, usually with increased daytime frequency and nocturia. M-cholinoblockers remain the drug of choice in the treatment of OAB, and beta3-agonists are used at high risk development of cognitive impairment due to anticholinergic load. The objective of our work is to evaluate the efficacy and safety of trospium chloride in elderly patients with OAB refractory to mirabegron (beta-3-agonist). After 24 weeks, 16 out of 22 patients (aged from 65 to 80 years) had positive results and continued treatment, which was 72.7 %. At the same time, 12 patients used a dose of 45 mg and 4 patients 60 mg of trospium chloride. The reasons for interruption of treatment were insufficient efficacy in 2 patients and side effects in 4 patients (dry month – 1, constipation – 2 and residual urine – 1). It is important to note that none of the patients have been observed to have deterioration of cognitive function. Thus, we conclude that trospium chloride is a reliable M-cholinoblocker for the treatment of OAB, including elderly patients at risk of developing CNS dysfunction as a result of anticholinergic load.
About the Authors
G. G. Krivoborodov
Russian Gerontology Research and Clinical Centre; Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Krivoborodov Grigory Georgievich
Moscow
D. A. Shirin
Russian Gerontology Research and Clinical Centre
Russian Federation
Russian Federation
Moscow
References
1. Abrams P., Cardozo L., Fall M., et al. The standardisation of terminology of lower urinary tract function: Report from the Standardisation Subcommittee of the International Continence Society. Neurourol Urodyn. 2002 ; 21 (2) : 167–178. doi: 10.1002/nau.10052.
2. Milsom I., Abrams P., Cardozo L., et al. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int. 2001; 87 (9) : 760–766. doi: 10.1046/j.1464-410x.2001.02228.x. Erratum in: BJU Int. 2001 ; 88 (7) : 807.
3. Irwin D. E., Milsom I., Hunskaar S., et al. Populationbased survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006 ; 50 (6) : 1306–1315. doi: 10.1016/j.eururo.2006.09.019.
4. GHE: Life expectancy and healthy life expectancy. [Electronic resourse] // WHO. 2022. Access mode: https://www.who.int/data/gho/data/themes/mortality-and-global-healthestimates/ghe-life-expectancy-and-healthy-life-expectancy, free.
5. Welk B. The impact of anticholinergics on cognitive function in patients with neurogenic lower urinary tract dysfuncton: A narrative review. Indian J Urol. 2024 ; 40 (2) : 82–87. doi: 10.4103/iju.iju_352_23.
6. Chapple C. R., Nazir J., Hakimi Z., et al. Persistence and adherence with mirabegron versus antimuscarinic agents in patients with overactive bladder: a retrospective observational study in UK clinical practice. Eur Urol. 2017 ; 72 (3) : 389–399. doi: 10.1016/j.eururo.2017.01.037.
7. Nakagomi H., Mitsui T., Shimura H., et al. Mirabegron for overactive bladder in frail patients 80 years or over (HOKUTO study). BMC Urol. 2022 ; 22 (1) : 40. doi: 10.1186/s12894-022-00989-7.
8. Doroshyenko O., Jetter A., Odenthal K. P., Fuhr U. Clinical pharmacokinetics of trospium chloride. Clin Pharmacokinet. 2005 ; 44 (7) : 701–720. doi: 10.2165/00003088-200544070-00003.
9. Staskin D., Sand P., Zinner N., et al. Once daily trospium chloride is effective and well tolerated for the treatment of overactive bladder: results from a multicenter phase III trial. J Urol. 2007 ; 178 (3 Pt 1) : 978–984. doi: 10.1016/j.juro.2007.05.058.
10. Tkacheva O. N., Krivoborodov G. G., Vorobyeva N. M., et al. Prevalence of urinary incontinence in people aged 65 years and older: results from the study EUCALYPTUS. Urologiya. 2024 ; (4) : 29–34. (In Russ.). doi: 10.18565/urology.2024.4.29-34.
11. Tkacheva O. N., Sharashkina N. V., Reshetova A. A., et al. Urinary incontinence in women over 60: associations between multimorbidity, frailty and other geriatric syndromes. Problemy standartizacii v zdravoohranenii = Health care Standardization Problems. 2021 ; 11-12: 61–68. (In Russ.). doi: 10.26347/1607-2502202111-12061-068.
12. Silva V. A., Souza K. L., D'Elboux M. J. Incontinência urinária e os critérios de fragilidade em idosos em atendimento ambulatorial [Urinary incontinence and the criteria of frailness among the elderly outpatients]. Rev Esc Enferm USP. 2011 ; 45 (3) : 672–678.
13. Nakagawa H., Niu K., Hozawa A., et al. Impact of nocturia on bone fracture and mortality in older individuals: a Japanese longitudinal cohort study. J Urol. 2010 ; 184 (4) : 1413–1418. doi: 10.1016/j.juro.2010.05.093.
14. Menarini M., Del Popolo G., Di Benedetto P., et al. Trospium chloride in patients with neurogenic detrusor overactivity: is dose titration of benefit to the patients? Int J Clin Pharmacol Ther. 2006 ; 44 (12) : 623–632. doi: 10.5414/cpp44623.
15. Isik A. T., Celik T., Bozoglu E., Doruk H. Trospium and cognition in patients with late onset Alzheimer disease. J Nutr Health Aging. 2009 ; 13 (8) : 672–676. doi: 10.1007/s12603-009-0196-5.
16. Krivoborodov G. G., Tur E. I., Efremov N. S., SHkol’nikov M. E. High doses of trospium chloride in patients with idiopathic overactive bladder. Data of large-scale, multicenter observational program «Resource». Urologiya. 2016 ; (4) : 29–34. (In Russ.).
Review
For citations:
Krivoborodov G.G., Shirin D.A. Trospium chloride in elderly patients with idiopathic overactive bladder refractory to mirabegron. Russian Journal of Geriatric Medicine. 2025;(4):580-584. (In Russ.) https://doi.org/10.37586/2686-8636-4-2025-580-584
Views:
31
Email this article 